Information Provided By:
Fly News Breaks for March 5, 2019
TGTX
Mar 5, 2019 | 07:11 EDT
SunTrust analyst Peter Lawson lowered his price target on TG Therapeutics to $15, saying he has updated his model on the company's Marginal zone lymphoma readouts and the Follicular lymphoma data with new timing estimates for catalysts in those programs. The analyst also keeps his Buy rating on the shares longer term, saying he remains positive on TG Therapeutics' "capital-efficient strategy of utilizing therapeutics to develop novel combination therapies" and sees its proprietary doublet TG-1101 + TGR-1202 potentially serving patients across all lines of Chronic Lymphocytic Leukemia.
News For TGTX From the Last 2 Days
There are no results for your query TGTX